A Dec. 21 article published in Law360 examines the U.S. Food and Drug Administration (FDA) latest development to limit digital software regulations. The article was authored by life sciences partner Gregory Levine (Washington, D.C.) and corporate practice associate Rebecca Williams (Washington, D.C.)
The authors address two draft guidance documents describing the types of software functions the FDA will not regulate, including clinical and patient decision support software, as well as the FDA adopting final guidance on clinical evaluation of software as a medical device. These actions represent the FDA’s efforts to oversee the digital health products under a risk-based model and prioritize innovation.
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.